The FDA approved the monoclonal antibody Herceptin (Trastuzumab) for treatment of metastatic breast cancer
On Sept. 25, 1998, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Herceptin (Trastuzumab) for treatment of metastatic breast cancer in patients with tumors that produce excess amounts of a protein called HER-2.
Approximately 30% of breast cancer tumors produce excess amounts of HER-2.
Tags:
Source: U.S. Food and Drug Administration
Credit: PDF: Genentech approval letter from FDA.
